A team of Stanford Medicine researchers has identified a naturally occurring molecule in the human body that suppresses appetite as powerfully as semaglutide — but without the nausea, constipation, or muscle loss that plague GLP-1 drug users. For anyone following evidence-based nutritionist guidance on weight management, this discovery signals that a targeted, body-friendly alternative to Ozempic may already exist inside us.
What the Research Found
The molecule, called BRP, is a tiny peptide made of just 12 amino acids — a fraction of the complexity of semaglutide. Stanford scientists discovered it using an AI tool called Peptide Predictor, which screened more than 2,600 peptide fragments from the human prohormone database, looking for candidates that might act like appetite-regulating hormones. The algorithm identified 373 prohormone candidates; BRP emerged as the standout.
In animal studies, a single injection of BRP before a meal reduced food intake by up to 50% within one hour. Over a 14-day trial in obese mice, treated animals lost 3 grams while controls gained 3 grams — a 6-gram swing on a body that weighs roughly 40 grams. As reported by ScienceDaily / Stanford Medicine, the study was led by senior research scientist Laetitia Coassolo and Dr. Katrin Svensson, and published in Nature on March 5, 2025.
Why It Works Differently From Ozempic
The key distinction is specificity. Semaglutide (Ozempic, Wegovy) binds GLP-1 receptors throughout the body — gut, pancreas, heart, kidneys — which drives its broad side-effect profile. BRP acts almost exclusively in the hypothalamus, the brain region that governs hunger and metabolism. In lab tests, it increased neuronal activity tenfold compared to controls in the relevant hypothalamic circuits, with no measurable signal elsewhere. That precision is why animal subjects showed no signs of nausea or lean-mass loss.
What Comes Next
BRP is still in preclinical stages; human trials have not yet been announced. Researchers note that the AI-driven discovery method itself is the bigger headline: Peptide Predictor scanned 20,000 human genes to surface 373 prohormone candidates, a process that would take years by conventional biochemistry. The same pipeline could uncover other endogenous appetite or metabolic regulators. For the nutrition field, the implication is clear — future weight-management interventions may work with the body’s own signaling molecules rather than synthetic analogues, reducing the tolerability trade-offs that currently limit GLP-1 drug adherence.